Paolo Tarantino: HER2: a remarkable story of precision oncology
Paolo Tarantino shared on X:
“HER2: a remarkable story of precision oncology.
Check this wonderful Nature review on targeting HER2 beyond breast. Important to remember: now that we have an agnostic anti-HER2 drug approved (T-DXd), every adv cancer patient should get HER2 testing!
‘HER2-targeted therapies beyond breast cancer — an update‘
Authors: Jeesun Yoon, Do-Youn Oh.”
Source: Paolo Tarantino/X
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.